drugset / Trial / NCT05876364
Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)
Non-randomizedSequentialOpen-labelPrevention
Summary
This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.
Timeline
- Start
- 2021-11-19
- Primary completion
- 2022-06-13
- Completion
- 2023-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QTP104 | Unknown | 1 ug | Intramuscular |
| Subject | QTP104 | Unknown | 5 ug | Intramuscular |
| Subject | QTP104 | Unknown | 25 ug | Intramuscular |